- Home
- STSS vs NRXP Comparison
STSS vs NRXP Comparison
Compare STSS & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STSS | NRXP |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 62.2M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | STSS | NRXP |
|---|---|---|
| Price | $1.77 | $1.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.67 |
| AVG Volume (30 Days) | ★ 638.4K | 621.1K |
| Earning Date | 03-26-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $306,344.00 | $242,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $847.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $1.58 |
| 52 Week High | $211.20 | $3.84 |
Technical Indicators
Market Signals| Indicator | STSS | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 43.11 | 40.04 |
| Support Level | $1.58 | $1.70 |
| Resistance Level | $1.85 | $2.00 |
| Average True Range (ATR) | 0.18 | 0.15 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 38.12 | 25.23 |
Price Performance
Historical ComparisonAbout STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.